AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05890144 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Little Canoe
Description: The Little Canoe involves a brief, 2-hour, interactive, computer-based Indigenous race-bias education session that is offered in a computer lab with a researcher present and followed up with 2 reinforcement/reminder emails that ask questions about strategy usage at 6 and 8 weeks after the session
Study NCT05890144 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: The control is a primary care-related training program that is time-attention matched to Arm 1 but does not contain any content on anti-bias, anti-oppression, Indigenous peoples, or any content related to the unannounced Indigenous standardized patient encounter.
Study NCT02138773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin formulation-A
Description: oral
Study NCT02138773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin formulation-B
Description: oral
Study NCT04389216 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cool-tip electrode for Radiofrequency Ablation
Description: Radiofrequency ablation of the tumour in the surgery group, associated whith axillary surgery when applicable
Study NCT02360995 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triclosan/fluoride toothpaste
Description: Brush whole mouth with Total toothpaste (sold in the US), using a Total 360 toothbrush, 2 times/day for 6 weeks (study duration).
Study NCT02360995 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: stannous fluoride toothpaste
Description: Brush whole mouth with Crest Pro-Health toothpaste using an Oral B Pro-Health toothbrush for 1 minute, 2 times/day for 6 weeks (study duration).
Study NCT02360995 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: fluoride toothpaste
Description: Brush whole mouth with Crest Cavity Protection toothpaste using an Oral B Indicator toothbrush for 1 minute, 2 times/day for 6 weeks (study duration).
Study NCT02360995 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluoride Mouthwash
Description: Immediately after each toothbrushing rinse whole mouth with 20 ml of Crest fluoride Mouthrinse for 30 seconds each time.
Study NCT02360995 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cetylpyridinium chloride Mouthwash
Description: Immediately after each toothbrushing rinse whole mouth with 20 ml of Crest Pro-Health Mouthrinse for 30 seconds each time.
Study NCT02796703 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Heat Inactivated probiotics
Description: Biotikid, a probiotic mixture, will be heated to 100 degrees Centigrade for 10 minutes to inactivate and then 1 tsp will be diluted in milk and give with feeds to treatment group
Study NCT02796703 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 cc of milk will be given to control group
Study NCT04703387 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: transthoracic echocardiography
Description: Trans-mitral flow velocities (peak early diastolic E and peak late diastolic A) will be recorded with pulsed-wave Doppler, placing the sample volume at the mitral valve tips from the apical 4-chamber view; deceleration time of the E wave (DTE) will be measured. Peak early diastolic velocity will be obtained with tissue Doppler imaging (TDI), in the apical 4-chamber view, positioning the pulsed-wave Doppler sample volume at or 1 cm within the septal insertion sites of the mitral leaflets, so as to cover the longitudinal excursion of the mitral annulus in both systole and diastole. Then, the E/A ratio and the trans-mitral inflow E wave to mitral annular e' (E/e) will be calculated.Diaphragmatic thickness will be assessed in the zone of apposition of the diaphragm to the rib cage between the 8th and 10th intercostal spaces using a 3-12 MHz linear array probe , we will record changes in diaphragm vertical excursion using M-mode ultrasound.
Study NCT01081288 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Invitation for breast screening
Description: Invitation for breast screening to women in different age groups
Study NCT00820352 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bosentan
Description: 4 weeks of oral bosentan 62,5 mg b.i.d., followed by 8 weeks of 125 mg b.i.d.
Study NCT00820352 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo twice a day for 12 weeks
Study NCT03302650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Angiotensin II
Description: Patients will receive angiotensin-II at a starting dose of 20 ng/Kg/min.
Study NCT03302650 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Patients will receive normal saline.
Study NCT03302650 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: patients will receive norepinephrine infusion adjusted according to blood pressure
Study NCT03302650 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Norepinephrine
Description: patients will receive norepinephrine infusion adjusted according to blood pressure
Study NCT02431338 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning
Description: Intermittent arm ischemia through four cycles of alternating 5-minute inflation followed by 5-minute deflation of a blood pressure cuff placed around the upper arm.
Study NCT03110926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Description: Induction Chemotherapy
Study NCT03110926 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Chemoradiation
Description: Chemoradiation
Study NCT01381484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10% Argireline
Description: 10% Argireline (La jolie gel®, Pacific health care, Thailand) were instructed to apply the gel over the face and periorbital area twice daily for a period of 3 months.
Study NCT04673968 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: prehabilitation
Description: inhospital exercise training 5 times/week, 5\~6 weeks during nCRT; home exercise 5 times/week, 5\~6 weeks, between completion of nCRT and before surgery
Study NCT03039452 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity interval training
Description: Each training session will consist of a 3-5 minute warm-up, followed by 10 repetitions of 1-minute bouts at individualized training intensity with 1-minute rest periods.
Study NCT03267836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: -10mg/kg IV
Study NCT03267836 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Therapy
Description: -Proton therapy will start concurrently with the first dose of avelumab (up to 3 days before or after is permissible) and will be administered once daily during weekdays (Monday through Friday).
Study NCT03267836 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: -Standard of care
Study NCT00935948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imescard compound water smartweed ointment
Description: Patients in this arm were instructed to apply the ointment after waking up, after evacuations and before bedtime, for 5 days.
Study NCT00935948 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in this arm received placebo, with the exact same appearance of the Imescard ointment, and were instructed to apply it at the same intervals and period.
Study NCT02031796 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CAVAREC Image Processing algorithm
Description: After deployment of the TAVI prosthesis, other trans catheter valve, or stent, but before the patient care episode is completed, a set of rotational x-ray angiography images will be acquired and reconstructed using the clinical DyanCT and research CAVAREC algorithms.
Study NCT03386318 — intervention group
Intervention type: DRUG
Intervention: Oxycodone
Description: Serum concentration per hour from 1 to 5 h
Study NCT01629992 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative counseling
Description: The intervention group received preoperative counseling by both orally and written. A written leaflet containing information was provided to each patient of this group.
Study NCT04195906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: SNF472
Description: Administered 3 times weekly by intravenous infusion through the hemodialysis machine in conjunction with the subject's hemodialysis sessions for 12 weeks
Study NCT04195906 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Placebo
Description: Administered 3 times weekly by intravenous infusion through the hemodialysis machine in conjunction with the subject's hemodialysis sessions fo 12 weeks
Study NCT04195906 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimatenl SNF472 (Open-label)
Description: Administered 3 times weekly by intravenous infusion through the hemodialysis machine in conjunction with the subject's hemodialysis sessions for 12 weeks
Study NCT02299882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Patient will be randomized to either vancomycin or no vancomycin. This treatment will take place prior to the closure of the incision from back surgery.
Study NCT00928395 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Urgent PC
Description: The Urgent PC Neuromodulation System is a minimally invasive neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve. The method of treatment is referred to as Percutaneous Tibial Nerve Stimulation (PTNS).
Study NCT02008318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galunisertib
Description: Administered orally
Study NCT02008318 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT03460275 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Osimertinib Mesylate Tablets
Description: Osimertinib 80mg oral administration daily until progression or occurring intolerable treatment-related toxic effects or patients withdrawing informed consent(Based on whichever occurs first)
Study NCT02829060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrofurantoin 100 MG, 7d
Description: 7 day course, 100 mg twice daily, PO
Study NCT02829060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gentamicin, 5mg/kg
Description: Peri-operative dose: 5 mg/kg of ideal body weight, IV
Study NCT02829060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ampicillin 2g
Description: Peri-operative dose: 2 grams, IV
Study NCT03659825 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone Ester
Description: Flavored sports drink containing deltaG (betahydroxybutyrate monoester) as the sole active ingredient, diluted with water.
Study NCT03659825 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Taste Matched Placebo
Description: Placebo that tastes similar to active intervention
Study NCT03659825 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypoxic exposure
Description: Participants will breath through a mask to provide the amount of oxygen typically seen at 16-17,000ft of altitude.
Study NCT03659825 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hypoxic exposure
Description: Participants will breath through a mask to provide the amount of oxygen typically seen at 16-17,000ft of altitude.
Study NCT01356368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin, Gemzar, Docetaxel, Alimta
Description: Patients will be assigned to treatment according to the molecular biological results which will analyze excision repair cross-complementing (ERCC1), ribonucleotide reductase subunit M1 (RRM1) and beta-tubulin genes in primary tumor cells which are present in tissues and peripheral blood.
Study NCT01613651 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: robot-assisted laparoscopic surgery
Description: Undergo RALP
Study NCT01613651 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01613651 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intraoperative complication management/prevention
Description: Undergo placement of pelvic drain
Study NCT03238547 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: semi-quantitative urine albumin-to-creatinine ratio test
Description: measurement of urine albumin-to-creatinine ratio using URiSCAN 2ACR, a semi-quantitative urine albumin-to-creatinine ratio test
Study NCT03238547 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: standard quantitative spot urine albumin-to-creatinine ratio
Description: measurement of urine albumin-to-creatinine ratio using a standard turbidimetric immunoassay
Study NCT01931410 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Misoprostol
Study NCT01749787 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered via infusion once per week for 5 weeks
Study NCT01749787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRTX-100 at 420 mcg
Study NCT01935258 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychosomatic therapy
Description: Psychosomatic therapy delivered by a psychosomatic therapist, consists of a combination of information and education delivery, relaxation therapy and mindfulness, cognitive approaches and activating therapy. This multi-component approach is captured into a protocol in which therapists are able to modify the treatment in order to deliver a tailor-made treatment for patients with MUS.
Study NCT01935258 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: care as usual
Description: usual care of the general practitioner
Study NCT01935258 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: care as usual
Description: usual care of the general practitioner
Study NCT03162887 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive a research team member-led breast cancer and mammogram educational module
Study NCT03162887 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Undergo a web-based decision counseling session
Study NCT03162887 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive a next steps document
Study NCT01861678 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High tie of IMA
Description: Conventional technique
Study NCT01861678 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low tie of IMA
Description: Technique for preserving left colic arterial perfusion
Study NCT04157712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALZ-801 or matching placebo
Study NCT00218556 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral treatment for depression
Description: Cognitive behavioral intervention to prevent depressive symptoms during treatment for hepatitis C
Study NCT02227745 — intervention group
Intervention type: DRUG
Intervention: Dorzolamide hydrochloride (2%)
Description: Subsequently photocoagulation treatment was applied according to the guidelines of the ETDRS, reevaluate the patient at 4 weeks.~Patient 1 drop of topical drug in the treaty provided every 8 hours for 4 weeks eye and again 4 weeks after cited for evaluation will be placed
Study NCT02227745 — intervention group
Intervention type: DRUG
Intervention: Placebo Sodium hyaluronate 4mg
Description: Intervention: Subsequently photocoagulation treatment was applied according to the guidelines of the ETDRS, reevaluate the patient at 4 weeks.~Patient 1 drop of topical drug in the treaty provided every 8 hours for 4 weeks eye and again 4 weeks after cited for evaluation will be placed.
Study NCT01369589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P-552
Description: P-552 will be administered as 10 mL mouth rinse to be swished in the mouth fro 30 seconds and then completely expectorated.
Study NCT03519880 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom Mask Interface
Description: Subjects enrolled in the study will received a custom designed, 3D printed, non-invasive ventilation mask interface.
Study NCT03631511 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: direct pulp capping with RetroMTA
Description: The study included seven caries-free third molars from three adults. These teeth were subjected to pulp exposure, direct capping with RetroMTA, and restoration with a composite resin. Seven months later, the teeth were clinically and radiographically evaluated. The teeth were then extracted and subjected to histological processing and evaluation.
Study NCT01146197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TREATMENT
Description: Patients with received in random order 75mg/day indometacin(chronoindocid®), 10-20 mg/day amiloride and 50-150 mg /day eplerenone (Inspra ®). The three 6 weeks-periods of treatment will be followed by six weeks washout period. 3-6 weeks before the first period of treatment, a supplementation with potassium and magnesium will be orally given, and maintained at the same dose throughout the study and stoped 6 weeks after the end of the third period of treatment.
Study NCT02829060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrofurantoin 100 mg, 48 hrs
Description: 48 hour course, 100 mg twice daily, PO
Study NCT02829060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gentamicin, 80 mg, 7d
Description: 7 day course, 80 mg daily, IM or IV
Study NCT02829060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gentamicin, 80 mg, 48hr
Description: 48 hour course, 80 mg daily, IM or IV
Study NCT02095418 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil, Corticosteroids
Description: tacrolimus (low dose, trough level of 5-12ng/ml)+Mycophenolate mofetil(500-1500mg/day\*, bid)+ Basiliximab + corticosteroids 500mg to 5mg or above (2 weeks)
Study NCT02095418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids, Mycophenolate mofetil
Description: tacrolimus (low dose, trough level of 5-12ng/ml)+Mycophenolate mofetil(500-1000mg/day\*, bid)+ Basiliximab + corticosteroids 500mg to 5mg or above (3 month±2weeks)
Study NCT02006888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI-10090
Study NCT02006888 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03485391 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure
Description: Practice guidelines have identified that trauma-focused psychotherapies have most evidence for treatment PTSD. Prolonged Exposure (PE) is one type of trauma-focused psychotherapy. PE teaches you to gradually approach trauma-related memories, feelings, and situations that you have been avoiding since your trauma. By confronting these challenges, you can decrease your PTSD symptoms. Treatment will last anywhere from 8-12 weeks for 75-90 minutes, once per week.
Study NCT03485391 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged Exposure
Description: Practice guidelines have identified that trauma-focused psychotherapies have most evidence for treatment PTSD. Prolonged Exposure (PE) is one type of trauma-focused psychotherapy. PE teaches you to gradually approach trauma-related memories, feelings, and situations that you have been avoiding since your trauma. By confronting these challenges, you can decrease your PTSD symptoms. Treatment will last anywhere from 8-12 weeks for 75-90 minutes, once per week.
Study NCT01727401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fondaparinux
Description: Fondaparinux once daily sc injections at a dose of 2.5 mg if renal clearance of creatinine above 50 ml/min or Fondaparinux once daily sc injections 1.5 mg if renal clearance of creatinine between 20 and 50 ml/min
Study NCT00261274 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: A-ECO
Study NCT00261274 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study NCT00371826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus (RAD001)
Study NCT00371826 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine (Calcineurin Inhibitor (CNI))
Study NCT00371826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine (Calcineurin Inhibitor (CNI))
Study NCT00371826 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisone/prednisone
Study NCT00371826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisone/prednisone
Study NCT00371826 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate sodium (MPA)
Study NCT00371826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate sodium (MPA)
Study NCT00481143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ICL670/Deferasirox
Study NCT00219739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate 400 mg
Study NCT01369589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as 10 mL mouth rinse to be swished in the mouth for 30 seconds and then completely expectorated.
Study NCT02404454 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hysteroscopic metroplasty